Table 2 Serological, clinical, and functional parameters during the five year study period

Responders

0 M

21.7 ± 18.2

1.9 ± 1.6

47.1 ± 16.8

59.5 ± 15.3

5.9 ± 1.3

64.9 ± 16.9

50.5 ± 21.4

3 M

13.5 ± 12.8

1.3 ± 1.9

44.5 ± 17.5

54.2 ± 17.3

5.7 ± 1.4

61.3 ± 15.1

45.4 ± 22.1

6 M

10.4 ± 8.8

1.0 ± 1.4

38.1 ± 22.2

46.5 ± 20.1***

5.6 ± 1.3

55.3 ± 12.4*

40.6 ± 21.6*

12 M

11.9 ± 12.4

1.1 ± 1.4

32.1 ± 20.1**

40.9 ± 19.4*

5.1 ± 1.6***

41.1 ± 11.9*

35.6 ± 19.9*

24 M

10.9 ± 10.2

1.2 ± 1.9

27.2 ± 17.4*

38.9 ± 20.9*

4.8 ± 1.4*

37.8 ± 10.9*

32.4 ± 17.8*

36 M

14.2 ± 12.6

0.9 ± 1.1

23.4 ± 15.3*

31.4 ± 18.1*

4.7 ± 1.4*

36.2 ± 10.1*

30.5 ± 18.7*

48 M

13.1 ± 8.1

0.7 ± 1.6*

20.4 ± 13.9*

28.2 ± 18.8*

4.5 ± 1.3*

32.6 ± 12.1*

25.2 ± 19.6*

60 M

11.5 ± 8.8

0.8 ± 1.5*

15.8 ± 12.2*

25.8 ± 18.6*

4.2 ± 1.4*

30.8 ± 13.2

20.3 ± 19.8

p

0.087

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

Non-responders

0 M

31.0 ± 25.1

1.6 ± 1.5

52.2 ± 25.1

59.9 ± 19.6

5.4 ± 1.6

62.9 ± 18.8

61.1 ± 19.0

3 M

22.2 ± 22.6

1.4 ± 1.7

45.5 ± 21.9

55.7 ± 19.1

5.3 ± 1.6

57.2 ± 22.3

59.2 ± 22.9

6 M

21.5 ± 7.1

1.4 ± 1.6

43.2 ± 23.1

53.7 ± 19.9

5.0 ± 1.4

55.4 ± 20.6

60.5 ± 21.1

12 M

22.5 ± 20.4

1.4 ± 1.4

37.1 ± 24.9

23.0 ± 43.9

4.8 ± 1.6

47.8 ± 21.3

49.2 ± 20.0

24 M

17.9 ± 12.9

1.5 ± 3.1

24.9 ± 15.6

39.1 ± 25.6

4.9 ± 1.4

49.7 ± 22.2

55.5 ± 22.0

36 M

22.3 ± 14.1

1.4 ± 1.3

39.6 ± 27.9

38.8 ± 26.9

4.2 ± 2.2

50.2 ± 18.8

52.4 ± 19.7

48 M

23.5 ± 22.7

1.4 ± 2.1

33.4 ± 25.5

35.1 ± 23.3

4.1 ± 1.4

57.3 ± 17.4

60.6 ± 20.1

60 M

21.9 ± 15.8

1.6 ± 2.3

45.5 ± 25.1

43.1 ± 21.7

4.1 ± 1.5

58.2 ± 18.5

65.1 ± 19.8